Kiadis and Celmed BioSciences merged to form an oncology-focused company, Kiadis Pharma. The resulting company will be dedicated to in-house pharmaceutical product development.
Kiadis Pharma currently has a small molecule pipeline with four products in clinical development. Its lead product, ATIR, allowed blood cancer patients who did not have access to a fully matched donor to successfully receive a transplantation of bone-marrow, reports the company. ATIR is currently in Phase I/II.
The new company’s product pipeline relies on three technology platforms that, Kiadis Pharma points out, form a strong foundation for the development of existing and future drugs.
Kiadis Pharma’s management team will be headed by Manja Bouman as CEO. It will be headquartered in The Netherlands and will have facilities in The Netherlands and Canada.